Predictors of HbA Treatment Response to Add-on Medication Following Metformin Monotherapy: a Population-based Cohort Study

Overview

Journal Sci Rep

Specialty Science

Date 2023 Nov 28

PMID 38017086

Authors

Wei Ying Tan

Wynne Hsu

Mong Li Lee

Ngiap Chuan Tan

Affiliations

Soon will be listed here.

Abstract

Evidence on the influence of patient characteristics on HbA treatment response for add-on medications in patients with type 2 diabetes (T2D) is unclear. This study aims to investigate the predictors of HbA treatment response for three add-on medications (sulfonylureas (SU), dipeptidyl peptidase-4 (DPP-4) and sodium-glucose cotransporter-2 (SGLT-2) inhibitor) in metformin monotherapy treated patients with T2D. This retrospective cohort study was conducted using the electronic health record data from six primary care clinics in Singapore. A total of 9748 adult patients with T2D on metformin monotherapy receiving SU, DPP-4 or SGLT-2 add-on were 1:1 propensity score matched to patients receiving other add-on medications. Patient demographics, laboratory results, diabetes related complications, comedications, and treatment response at two endpoints (HbA reduction ≥ 1% at 6th month, HbA goal attainment < 7% at 12th month) were examined. Multiple logistic regression analyses were used to identify patient characteristics associated with the treatment responses. After matching, there were 1073, 517, and 290 paired cohorts of SU, DPP-4 and SGLT-2 respectively. Besides baseline HbA, patients with longer hypertension disease duration and higher cholesterol HDL were associated with better treatment response to SU medication add-on. Lower estimated glomerular filtration rate (eGFR), and angiotensin-II receptor medications were associated with better treatment response to DPP-4 add-on. Lower cholesterol HDL, higher creatinine serum, absence of renal complications and beta-blockers medications were associated with better treatment response to SGLT-2 add-on. The cholesterol HDL, creatinine serum, eGFR, hypertension disease duration, angiotensin-II receptors and beta-blockers class of medications can influence the HbA treatment response for SU, DPP-4 and SGLT-2 add-on medications. Knowing the patients' characteristics that influence treatment response can assist in guiding clinical decisions when selecting the appropriate add-on medication, ultimately helping to prevent the development of diabetes-related complications.

Citing Articles

Prevalence of Vitamin B12 Deficiency in Patients With Type 2 Diabetes Mellitus on Metformin Therapy: A Cross-Sectional Study.

Asghar S, Tanvir H, Riaz A, Ejaz M, Akram M, Chowdhury Evan A Cureus. 2024; 16(10):e72184.

PMID: 39445039 PMC: 11498909. DOI: 10.7759/cureus.72184.

References

Zhang Z . Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med. 2016; 4(2):30. PMC: 4731595. DOI: 10.3978/j.issn.2305-5839.2015.12.63. View

Levey A, Inker L, Coresh J . GFR estimation: from physiology to public health. Am J Kidney Dis. 2014; 63(5):820-34. PMC: 4001724. DOI: 10.1053/j.ajkd.2013.12.006. View

Wilding J, Godec T, Khunti K, Pocock S, Fox R, Smeeth L . Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. BMC Med. 2018; 16(1):116. PMC: 6047134. DOI: 10.1186/s12916-018-1085-8. View

Lee J, Cho Y, Lee M, Kim Y, Lee Y, Lee B . Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors. Diabetes Metab J. 2019; 43(2):158-173. PMC: 6470102. DOI: 10.4093/dmj.2018.0057. View

Salvatore T, Galiero R, Caturano A, Rinaldi L, di Martino A, Albanese G . An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int J Mol Sci. 2022; 23(7). PMC: 8998569. DOI: 10.3390/ijms23073651. View

. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854-65. View

Thomas M, Cherney D . The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018; 61(10):2098-2107. DOI: 10.1007/s00125-018-4669-0. View

Malek M, Aghili R, Valojerdi A, Khamseh M . Predictors of Glycemic Response and Change in HbA1c Following Newly Initiated Basal Insulin Among Insulin Naïve Adults With Type 2 Diabetes. Acta Med Iran. 2017; 55(9):556-562. View

Home P, Shen C, Hasan M, Latif Z, Chen J, Galvez G . Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs. Diabetes Care. 2014; 37(5):1237-45. DOI: 10.2337/dc13-2413. View

10.

Cho Y, Cho S . Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort. Metabolism. 2018; 85:14-22. DOI: 10.1016/j.metabol.2018.03.009. View

11.

Rojas L, Gomes M . Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013; 5(1):6. PMC: 3607889. DOI: 10.1186/1758-5996-5-6. View

12.

Goh S, Ang S, Bee Y, Chen Y, Gardner D, Ho E . Ministry of Health Clinical Practice Guidelines: Diabetes Mellitus. Singapore Med J. 2014; 55(6):334-47. PMC: 4294061. DOI: 10.11622/smedj.2014079. View

13.

Andrew Fang H, Gao Q, Tan W, Lee M, Hsu W, Tan N . The effect of oral diabetes medications on glycated haemoglobin (HbA1c) in Asians in primary care: a retrospective cohort real-world data study. BMC Med. 2022; 20(1):22. PMC: 8790837. DOI: 10.1186/s12916-021-02221-z. View

14.

Wyncott D, Lyon C, Mounsey A . PURLs: Need an add-on to metformin? Consider this. J Fam Pract. 2017; 66(1):42-44. PMC: 5329113. View

15.

Hougen I, Whitlock R, Komenda P, Rigatto C, Clemens K, Tangri N . Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study. BMJ Open Diabetes Res Care. 2021; 9(2). PMC: 8718392. DOI: 10.1136/bmjdrc-2021-002352. View

16.

Turner R, Cull C, Frighi V, Holman R . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281(21):2005-12. DOI: 10.1001/jama.281.21.2005. View

17.

Miyoshi H, Kameda H, Yamashita K, Nakamura A, Kurihara Y . Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes. J Diabetes Investig. 2019; 10(6):1510-1517. PMC: 6825940. DOI: 10.1111/jdi.13064. View

18.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

19.

Allan V, Ramagopalan S, Mardekian J, Jenkins A, Li X, Pan X . Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res. 2020; 9(9):603-614. DOI: 10.2217/cer-2020-0013. View

20.

. 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2016; 40(Suppl 1):S64-S74. DOI: 10.2337/dc17-S011. View